Evidence map›Paper›PMID 40999102›Full record

ArticlePharmacoEconomics2025

Scoping Review of Productivity-Adjusted Life Years (PALYs): Methods, Applications and Policy Implications.

Zanfina Ademi, Dina Abushanab, Maria J Alfonso Arvez, Clara Marquina, Karl Vivoda, Janne Martikainen, Piia Lavikainen, Melanie Lloyd, Danny Liew

Abstract readScoping Review
In one paragraph

Article in PharmacoEconomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zanfina AdemiHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia. zanfina.ademi@monash.edu.ORCID 0000-0002-0625-3522
Dina AbushanabHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-4162-8617
Maria J Alfonso ArvezHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0003-1411-110X
Clara MarquinaHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0003-2582-0374
Karl VivodaHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0009-0005-7265-5596
Janne MartikainenSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-0855-3921
Piia LavikainenSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-3560-8860
Melanie LloydHealth Economics and Policy Evaluation Research (HEPER), Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-3889-5458
Danny LiewFaculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-0131-623X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo understand the application of productivity-adjusted life years (PALYs) as an outcome measure across various disease contexts.

methodsWe conducted a scoping review of studies published between 2018 and April 2025 that utilised PALYs to illustrate their potential applications and identify methodological approaches that have been applied. Using a citation-based search, we selected studies that applied PALYs to quantify societal health burdens in specific diseases or contexts. Extracted data included health conditions, country, timeframe, model type, outcomes, productivity index components, gross domestic product and sensitivity analysis. Findings were summarised through narrative synthesis.

resultsA total of 41 studies conducted between 2018 and 2025 were reviewed, including chronic diseases such as diabetes and cardiovascular diseases, as well as environmental factors. Conditions such as breast cancer, leukaemia, kidney disease, mental health, knee osteoarthritis, epilepsy and sleep apnoea had the lowest productivity indices. Most of these studies originated from high-income countries (n = 27), followed by upper-middle-income (n = 10), and lower-middle-income (n = 4) settings. Life table models were the most common methodological approach adopted (n = 26), followed by dynamic models (n = 10). Studies focused on disease prevention (n = 21) outnumbered those addressing disease management (n = 18). Most studies accounted for both absenteeism and presenteeism (n = 30). Estimates of productivity loss per person using gross domestic product ranged from US$1137 to AU$217,983 annually.

conclusionsPALYs have been utilised in diverse diseases and contexts, highlighting their utility in measuring societal health impacts. However, adding unpaid and informal work makes burden estimates more accurate. The increasing emphasis on prevention indicates a strategic change in health policy and economic assessment.

Indexed as

Cost of IllnessDisability-Adjusted Life YearsEfficiencyHealth PolicyQuality-Adjusted Life YearsChronic DiseaseHumans

Identifiers

PMID40999102
PMCPMC12602665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.